Literature DB >> 8153875

Therapeutic uses of recombinant complement protein inhibitors.

K R Kalli1, P Hsu, D T Fearon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8153875      PMCID： PMC7101590          DOI： 10.1007/bf01837368

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  117 in total

1.  Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement.

Authors:  M W Wang; L J Wright; M J Sims; D J White
Journal:  Scand J Immunol       Date:  1991-12       Impact factor: 3.487

2.  Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.

Authors:  R H Carter; M O Spycher; Y C Ng; R Hoffman; D T Fearon
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

3.  Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity.

Authors:  E M Adams; M C Brown; M Nunge; M Krych; J P Atkinson
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

4.  Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.

Authors:  M Reynes; J P Aubert; J H Cohen; J Audouin; V Tricottet; J Diebold; M D Kazatchkine
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

5.  Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H.

Authors:  J Alsenz; T F Schulz; J D Lambris; R B Sim; M P Dierich
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

6.  Effects of complement depletion on glomerular eicosanoid production and renal hemodynamics in rat nephrotoxic serum nephritis.

Authors:  J Garcia-Estan; R J Roman; E A Lianos; J Garancis
Journal:  J Lab Clin Med       Date:  1989-10

7.  Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.

Authors:  K R Kalli; P H Hsu; T J Bartow; J M Ahearn; A K Matsumoto; L B Klickstein; D T Fearon
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

8.  A receptor for the third component of complement in the human renal glomerulus.

Authors:  M C Gelfand; M M Frank; I Green
Journal:  J Exp Med       Date:  1975-10-01       Impact factor: 14.307

9.  Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type I. Duplication of genomic sequences occurs in association with a high molecular mass receptor allotype.

Authors:  W W Wong; C A Kennedy; E T Bonaccio; J G Wilson; L B Klickstein; J H Weis; D T Fearon
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

10.  A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP.

Authors:  J Rey-Campos; P Rubinstein; S Rodriguez de Cordoba
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307
View more
  13 in total

1.  Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.

Authors:  R J Quigg; C He; B K Hack; J J Alexander; B P Morgan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  A simple, yet highly accurate, QSAR model captures the complement inhibitory activity of compstatin.

Authors:  Chandrika Mulakala; John D Lambris; Yiannis Kaznessis
Journal:  Bioorg Med Chem       Date:  2006-12-13       Impact factor: 3.641

Review 3.  The future use of complement inhibitors for the treatment of neurological diseases.

Authors:  E G McGeer; P L McGeer
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

4.  Solution structure of Compstatin, a potent complement inhibitor.

Authors:  D Morikis; N Assa-Munt; A Sahu; J D Lambris
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

Review 5.  Complement components as potential therapeutic targets for asthma treatment.

Authors:  Mohammad Afzal Khan; Mark R Nicolls; Besiki Surguladze; Ismail Saadoun
Journal:  Respir Med       Date:  2014-01-15       Impact factor: 3.415

6.  Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues.

Authors:  Kwang-Seok Oh; Mee-Hyang Kweon; Ki-Hyeong Rhee; Keyong Ho Lee; Ha-Chin Sung
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

7.  A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement.

Authors:  M Ling; S J Piddlesden; B P Morgan
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 8.  Complement receptor type two (CR2,CR21): a target for influencing the humoral immune response and antigen-trapping.

Authors:  W M Prodinger
Journal:  Immunol Res       Date:  1999       Impact factor: 4.505

9.  Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis.

Authors:  B Schiller; C He; D J Salant; A Lim; J J Alexander; R J Quigg
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

10.  Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury.

Authors:  R J Quigg; C He; A Lim; D Berthiaume; J J Alexander; D Kraus; V M Holers
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.